D3 Oncology Solutions provides six-month free trial period for Via Oncology Pathways program

D3 Oncology Solutions today announced that it will provide its Via Oncology Pathways for a six-month free trial period to enable cancer programs to align the timing of their investment with a strategy for sharing potential savings with payors and other key stakeholders.  

Despite the widespread awareness of oncology pathways by oncologists today, the barriers to their adoption stem from a common set of issues confronting most oncology practices. Without the appropriate tools to evaluate historical physician treatment patterns, most practices are unable to project the impact of a pathways program on the cost of care, both to the payor and patient, as well as to the practice itself. In addition, the contracting vehicles for sharing value creation with health plans, accountable care organizations (ACOs), medical homes and referring physicians are difficult to achieve prior to actually implementing the pathways.  

In response to these issues, D3 Oncology Solutions is offering accelerated implementation of a non-customized version of its Via Oncology Pathways program to oncology practices and health systems for a trial period of six months at no charge. "This will allow cancer programs a risk-free vehicle for evaluating the impact to costs of their current treatment patterns compared to the Pathways and the time needed for contracting such value with key stakeholders," said Kathy Lokay, president of D3 Oncology Solutions.

Via Oncology Pathways are continually updated, evidence-based algorithms for common oncology and malignant hematology patient presentations. The Pathways are imbedded in a patient-specific, point-of-care, decision-support tool. Developed by expert panels of academic and community oncologists from around the country, Pathways have been shown to reduce variability in care while improving the quality of life for patients and lowering costs. These panels meet quarterly to establish and update their consensus around a single-best treatment for each state and stage of disease based on a hierarchy of efficacy, toxicity and cost.

Covering more than 85 percent of new cancer diagnoses, Via Oncology Pathways not only address the most prevalent diseases but also give strong attention to the disease presentations seen less frequently for which the potential for treatment variability increases. Via Oncology Pathways today cover 17 disease groups in medical oncology and 15 disease groups in radiation oncology. Advance care planning support also is built into the software to facilitate the physician's conversations with patients about their disease and care options.